Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-204 for Alzheimer's disease psychosis
2023-507325-42-00Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ACP-204 tartrate with Placebo to match ACP-204 (2 arms). Primary endpoint: Change from baseline in SAPS-H+D total score. Started Jul 2024; status: completed.
02
Drugs
remlifanserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-507325-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507325-42-00.